skip to main content
Idioma:
Refinado por: Nome da Publicação: Blood remover assunto: Male remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Byrd, John C. ; Hillmen, Peter ; O'Brien, Susan ; Barrientos, Jacqueline C. ; Reddy, Nishitha M. ; Coutre, Steven ; Tam, Constantine S. ; Mulligan, Stephen P. ; Jaeger, Ulrich ; Barr, Paul M. ; Furman, Richard R. ; Kipps, Thomas J. ; Thornton, Patrick ; Moreno, Carol ; Montillo, Marco ; Pagel, John M. ; Burger, Jan A. ; Woyach, Jennifer A. ; Dai, Sandra ; Vezan, Remus ; James, Danelle F. ; Brown, Jennifer R.

Blood, 2019-05, Vol.133 (19), p.2031-2042 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
2
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Material Type:
Artigo 		Adicionar ao Meu Espaço

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Barr, Paul M. ; Brown, Jennifer R. ; Hillmen, Peter ; O'Brien, Susan ; Barrientos, Jacqueline C. ; Reddy, Nishitha M. ; Coutre, Steven ; Mulligan, Stephen P. ; Jaeger, Ulrich ; Furman, Richard R. ; Cymbalista, Florence ; Montillo, Marco ; Dearden, Claire ; Robak, Tadeusz ; Moreno, Carol ; Pagel, John M. ; Burger, Jan A. ; Suzuki, Samuel ; Sukbuntherng, Juthamas ; Cole, George ; James, Danelle F. ; Byrd, John C.

Blood, 2017-05, Vol.129 (19), p.2612-2615 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Boidol, Bernd ; Kornauth, Christoph ; van der Kouwe, Emiel ; Prutsch, Nicole ; Kazianka, Lukas ; Gültekin, Sinan ; Hoermann, Gregor ; Mayerhoefer, Marius E. ; Hopfinger, Georg ; Hauswirth, Alexander ; Panny, Michael ; Aretin, Marie-Bernadette ; Hilgarth, Bernadette ; Sperr, Wolfgang R. ; Valent, Peter ; Simonitsch-Klupp, Ingrid ; Moriggl, Richard ; Merkel, Olaf ; Kenner, Lukas ; Jäger, Ulrich ; Kubicek, Stefan ; Staber, Philipp B.

Blood, 2017-12, Vol.130 (23), p.2499-2503 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
4
Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials
Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials

Spina, Michele ; Jaeger, Ulrich ; Sparano, Joseph A. ; Talamini, Renato ; Simonelli, Cecilia ; Michieli, Mariagrazia ; Rossi, Giuseppe ; Nigra, Ezio ; Berretta, Massimiliano ; Cattaneo, Chiara ; Rieger, Armin C. ; Vaccher, Emanuela ; Tirelli, Umberto

Blood, 2005-03, Vol.105 (5), p.1891-1897 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível

Citações Citado por
5
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
Material Type:
Artigo 		Adicionar ao Meu Espaço

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

Mueller, Niklas ; Wicklein, Daniel ; Eisenwort, Gregor ; Jawhar, Mohamad ; Berger, Daniela ; Stefanzl, Gabriele ; Greiner, Georg ; Boehm, Alexandra ; Kornauth, Christoph ; Muellauer, Leonhard ; Sehner, Susanne ; Hoermann, Gregor ; Sperr, Wolfgang R. ; Staber, Philipp B. ; Jaeger, Ulrich ; Zuber, Johannes ; Arock, Michel ; Schumacher, Udo ; Reiter, Andreas ; Valent, Peter

Blood, 2018-11, Vol.132 (18), p.1936-1950 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
6
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
Material Type:
Artigo 		Adicionar ao Meu Espaço

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

Pabst, Thomas ; Vellenga, Edo ; van Putten, Wim ; Schouten, Harry C. ; Graux, Carlos ; Vekemans, Marie-Christiane ; Biemond, Bart ; Sonneveld, Peter ; Passweg, Jakob ; Verdonck, Leo ; Legdeur, Marie-Cecile ; Theobald, Matthias ; Jacky, Emanuel ; Bargetzi, Mario ; Maertens, Johan ; Ossenkoppele, Gert Jan ; Löwenberg, Bob

Blood, 2012-06, Vol.119 (23), p.5367-5373 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível

Citações Citado por
7
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Löwenberg, Bob ; Beck, Joachim ; Graux, Carlos ; van Putten, Wim ; Schouten, Harry C. ; Verdonck, Leo F. ; Ferrant, Augustin ; Sonneveld, Pieter ; Jongen-Lavrencic, Mojca ; von Lilienfeld-Toal, Marie ; Biemond, Bart J. ; Vellenga, Edo ; Breems, Dimitri ; de Muijnck, Hilde ; Schaafsma, Ron ; Verhoef, Gregor ; Döhner, Hartmut ; Gratwohl, Alois ; Pabst, Thomas ; Ossenkoppele, Gert J. ; Maertens, Johan ; for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) ; German Austrian AML Study Group (AMLSG) ; Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)

Blood, 2010-04, Vol.115 (13), p.2586-2591 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível

Citações Citado por
8
Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - A randomized phase-III study
Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - A randomized phase-III study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - A randomized phase-III study

GEISSLER, K ; KOLLER, E ; SCHWARZINGER, I ; MANNHALTER, C ; JAEGER, U ; HEINZ, R ; LINKESCH, W ; LECHNER, K ; HUBMANN, E ; NIEDERWIESER, D ; HINTERBERGER, W ; GEISSLER, D ; KYRLE, P ; KNÖBL, P ; PABINGER, I ; THALHAMMER, R

Blood, 1997-07, Vol.90 (2), p.590-596 [Periódico revisado por pares]

Washington, DC: The Americain Society of Hematology

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.